| Literature DB >> 31184980 |
Ryota Kikuchi1, Yuki Iwai1, Yusuke Watanabe1, Hiroyuki Nakamura1, Kazutetsu Aoshiba1.
Abstract
A 68-year-old woman under maintenance hemodialysis was admitted to our hospital with fever and dyspnea that had developed two days after the second vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV23). She had received the first vaccination with PPV23 five years earlier without any complications. Chest X-ray and computed tomography (CT) showed bilateral diffuse infiltrative and ground glass opacities. Bronchoalveolar lavage (BAL) revealed an abundance of eosinophils. A positive test result for PPV23 was obtained in the drug lymphocyte stimulation test. The patient was diagnosed as having eosinophilic pneumonia caused by the pneumococcal vaccination and was successfully treated by 3-week's administration of a steroid. No disease recurrence was observed at the three-month follow-up. Thus, EP is a rare, but life-threating condition following pneumococcal vaccination.Entities:
Keywords: Pneumococcal vaccine; eosinophilic pneumonia; respiratory insufficiency
Mesh:
Substances:
Year: 2019 PMID: 31184980 PMCID: PMC6930081 DOI: 10.1080/21645515.2019.1631134
Source DB: PubMed Journal: Hum Vaccin Immunother ISSN: 2164-5515 Impact factor: 3.452